Loading
A phase 3 trial of Tiragolumab, Atezolizumab, Carboplatin and Etoposide in small-cell lung cancer, run by Hoffmann-La Roche, now completed.
Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT04665856 by Hoffmann-La Roche, with 123 participants enrolled, started 2020-12-21 and reached its primary completion in 2023-08-31. Interventions recorded: Tiragolumab, Atezolizumab, Carboplatin, Etoposide and Tiragolumab Matching Placebo. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
123 enrolled.
95% CI 4.30 to 6.77; Figures from the ClinicalTrials.gov results section (first posted 2025-10-29), not from a publication · 95% CI 4.53 to 7.89
Source95% CI 10.35 to 22.44; Figures from the ClinicalTrials.gov results section (first posted 2025-10-29), not from a publication · 95% CI 14.26 to 20.86
Source95% CI 45.01 to 71.63; Figures from the ClinicalTrials.gov results section (first posted 2025-10-29), not from a publication · 95% CI 68.13 to 90.30
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS)primary | Placebo + Atezolizumab + Carboplatin + Etoposide | 56 | 5.39 months | 0.65 (0.43 to 0.97) | 0.0348 | link |
| Tiragolumab + Atezolizumab + Carboplatin + Etoposide | 54 | 5.59 months | ||||
| Overall Survival (OS) in the PASprimary | Placebo + Atezolizumab + Carboplatin + Etoposide | 56 | 13.54 months | 0.89 (0.56 to 1.4) | 0.6105 | link |
| Tiragolumab + Atezolizumab + Carboplatin + Etoposide | 54 | 18.69 months | ||||
| Investigator-assessed Confirmed Objective Response Rate (ORR) in the PAS | Placebo + Atezolizumab + Carboplatin + Etoposide | 56 | 58.9% | - | 0.0136 | link |
| Tiragolumab + Atezolizumab + Carboplatin + Etoposide | 54 | 81.5% |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares TIGIT blockade, Tiragolumab, Flatiron Health (Roche), Atezolizumab and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Carboplatin and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Small-cell lung cancer and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/